In an 88-year-old female with dementia who is confused, reaches down, and experiences crying episodes while taking quetiapine (Seroquel) 25 mg at bedtime and clonidine for hypertension, what medication should be prescribed?

Do Not Add Medications—Prioritize Non-Pharmacologic Interventions and Consider Deprescribing Quetiapine

In this 88-year-old woman with dementia already taking quetiapine 25 mg at bedtime, I strongly recommend against adding any new medications and instead advocate for a trial of non-pharmacologic interventions first, with serious consideration of tapering or discontinuing the quetiapine given its significant mortality risk in this population.

Critical Safety Concerns with Current Regimen

The patient is already on quetiapine (Seroquel), which carries a black box warning for increased mortality in elderly patients with dementia-related psychosis 1. The FDA label explicitly states that elderly patients with dementia-related psychosis treated with antipsychotic drugs have a 1.6 to 1.7 times increased risk of death compared to placebo, with death rates of 4.5% versus 2.6% over 10 weeks 1. Quetiapine is not approved for dementia-related behavioral symptoms 1.

Recent 2025 data demonstrates that even low-dose quetiapine for insomnia in older adults is associated with:

• 3.1-fold increased mortality risk compared to trazodone (HR 3.1,95% CI 1.2-8.1)
• 8.1-fold increased dementia progression risk compared to trazodone (HR 8.1,95% CI 4.1-15.8)
• 2.8-fold increased fall risk compared to trazodone (HR 2.8,95% CI 1.4-5.3) 2

Why Not to Add More Medications

The Evidence Against Polypharmacy

The 2016 APA guidelines emphasize that antipsychotic benefits in dementia are "at best small" while adverse effects are "clinically significant" 3. Adding another medication would compound these risks without addressing the underlying behavioral triggers.

Specific Medication Risks to Avoid

• Benzodiazepines: The 2025 JAGS systematic review found midazolam increased adverse events 5-fold (OR 5.25) in older adults with agitation 4. Benzodiazepines pose "excessive risk" in this population 4.
• Additional antipsychotics: Would increase mortality risk further
• Antidepressants with quetiapine: Risk of serotonin syndrome, as documented in a case report of SS when quetiapine was combined with trazodone and sertraline 5

Recommended Management Algorithm

Step 1: Identify and Address Behavioral Triggers (First-Line)

Before any medication changes, systematically evaluate:

• Pain assessment: Use PAINAD scale or similar for non-verbal patients—unrecognized pain is a common cause of agitation
• Urinary retention or constipation: Check bladder scan, last bowel movement
• Environmental factors: Overstimulation, unfamiliar caregivers, disrupted sleep-wake cycle
• Unmet needs: Hunger, thirst, need for toileting, boredom
• "Reaching down" behavior: May indicate perineal discomfort, urinary issues, or repetitive behavior from frontal lobe dysfunction

Step 2: Implement Non-Pharmacologic Interventions

• Person-centered communication techniques
• Structured daily routine with meaningful activities
• Music therapy or sensory interventions
• Caregiver education on redirection techniques
• Optimize sleep hygiene (avoid daytime napping, morning light exposure)

Step 3: Consider Deprescribing Quetiapine

Given the mortality data 2, attempt a gradual taper:

• Reduce by 12.5 mg every 1-2 weeks
• Monitor for symptom recurrence
• The crying episodes may actually improve off quetiapine, as emotional lability can be a side effect

Step 4: Only If Dangerous Agitation Persists

If non-pharmacologic approaches fail AND there is dangerous agitation (risk of harm to self/others), the 2025 JAGS data shows quetiapine had the lowest adverse event rate among antipsychotics (OR 0.27 compared to haloperidol) 4. However, this does NOT outweigh the mortality risk demonstrated in 2.

If an antipsychotic is absolutely necessary for dangerous behaviors:

• Use the lowest effective dose (12.5-25 mg)
• Set a specific time-limited trial (2-4 weeks)
• Document target symptoms and reassess weekly
• Plan for discontinuation once acute crisis resolves

Critical Pitfalls to Avoid

1. Do not add benzodiazepines: Highest adverse event profile in older adults 4
2. Do not increase quetiapine dose: Higher doses exponentially increase mortality risk
3. Do not add multiple psychotropics: Increases fall risk, delirium, and drug interactions 6
4. Do not ignore the clonidine: May contribute to confusion through hypotension—check orthostatic vital signs
5. Do not assume crying = depression requiring antidepressants: Pseudobulbar affect is common in dementia and adding SSRIs with quetiapine risks serotonin syndrome 5

Bottom Line

The answer to "what to prescribe" is: nothing. The evidence strongly supports deprescribing rather than adding medications in this scenario 3, 2. The patient's symptoms likely reflect unmet needs or medication side effects rather than a need for additional pharmacotherapy. Focus on identifying reversible causes and implementing evidence-based non-pharmacologic strategies that improve quality of life without increasing mortality risk.